Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Int Immunopharmacol ; 101(Pt A): 108189, 2021 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-34601327

RESUMO

Behçet's disease is a chronic systemic inflammatory disorder associated with a cytokine profile disruption and increased nitric oxide levels. In our current study we sought to evaluate the in-vitro modulatory effect of nicotine, the principal alkaloid of tobacco, on nitric oxide (NO), interleukin 1ß (IL-1ß) and interleukin 37 (IL-37) production during Behçet's disease. Peripheral blood mononuclear cells cultures were performed with or without nicotine (200 µg/ml). Culture supernatants were harvested after 24 h of incubation. NO, IL-1ß and IL-37 measurements were, respectively, performed by modified Griess method and ELISA sandwich. Our results showed that nicotine significantly reduced NO and IL-1ß levels in patients with Behçet's disease, while it increased IL-37 production. Our results showed no sex differences in the effects of nicotine on the production of nitric oxide and IL-1ß nor IL-37 in PBMC of patients. Our findings suggest that nicotine may provide a potential therapeutic strategy targeting inflammation during Behçet's disease.


Assuntos
Síndrome de Behçet/tratamento farmacológico , Agentes de Imunomodulação/farmacologia , Interleucina-1/metabolismo , Interleucina-1beta/metabolismo , Leucócitos Mononucleares/efeitos dos fármacos , Nicotina/farmacologia , Óxido Nítrico/metabolismo , Adulto , Síndrome de Behçet/imunologia , Feminino , Humanos , Leucócitos Mononucleares/metabolismo , Masculino , Pessoa de Meia-Idade , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA